BMY-28100 IN OTORHINOLARYNGEAL INFECTIONS
スポンサーリンク
概要
- 論文の詳細を見る
We studied the clinical efficacy of BMY-28100 in 36 patients with otorhinolaryngeal infections.<BR>1) BMY-28100 at 250mg was administered orally three or four times daily after a meal.<BR>2) The clinical efficacy rate was: 77.8% in acute otitis media (9 cases), 62.5% in acute exacerbation of chronic otitis media (8), 77.8% in acute tonsillitis (9), 75.0% in acute sinusitis (4), and 83.3% in other infections (6). The overall clinical efficacy rate was 75.0%.<BR>3) The bacteriological eradication rate was 100%.<BR>4) No adverse reaction was observed. Abnormal laboratory findings were detected in two cases, namely, elevation of GPT and of GOT·GPT.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.